ENXTPA:MEDCLPharmaceuticals
A Look At MedinCell (ENXTPA:MEDCL) Valuation After EMA Accepts TEV-749 Marketing Authorization Application
Teva Pharmaceuticals and MedinCell (ENXTPA:MEDCL) have reached a key regulatory checkpoint, with the European Medicines Agency accepting the Marketing Authorization Application for TEV-749, a long acting injectable olanzapine for schizophrenia.
See our latest analysis for MedinCell.
The EMA update comes after a strong period for the stock, with a 30 day share price return of 15.37% and a 1 year total shareholder return of 59.14%, suggesting momentum is building around MedinCell's pipeline and...